This brought together EU health commissioner Stella Kyriakides and her colleague Thierry Breton, who heads up a vaccines task force, along with officials from the seven pharmaceutical companies that are currently producing vaccines for use in the EU. [ Ссылка ]
All stressed the “unprecedented” speed at which COVID vaccines were developed but also spoke of the “difficulties” they face in mass production and logistics across Europe and beyond.
Canfin, who chaired the special hearing – ‘How to increase the capacity of COVID-19 vaccine production and improve delivery’ - said the European Parliament will “continue to push for faster vaccination efforts across Europe,” adding, “This was the point of this hearing.”
The French MEP said, “Parliament will play its role fully to win the vaccine deployment battle. The contact group put in place by the European Parliament and European Commission will further strengthen our role.”
ENVI-ITRE Hearing on enhancing production capacity and delivery of COVID-19 Vaccines.
This joint hearing entitled "How to increase the capacity of COVID-19 vaccine production and improve delivery" will give ENVI and ITRE Members the opportunity to debate ways of removing obstacles to faster commercialisation, manufacturing and distribution of vaccines with CEOs of leading pharmaceutical companies, including AstraZeneca, Moderna, CureVac and Novavax.
#eudebates #Covid_19 #coronavirus #Corona #COVD19 #Health #COVID #vaccine #CureVac #Moderna #AstraZeneca #Novavax #Pfizer #Sanofi
Commissioners Breton and Kyriakides participate with the Co-Director of the Global Health Centre in Geneva and representatives from Johnson&Johnson, Pfizer and Sanofi.
[ Ссылка ] #eudebates
MEPs quizzed CEOs and representatives of leading pharmaceutical companies, including AstraZeneca, Moderna, CureVac, Novavax, Pfizer and Sanofi, on how to remove obstacles to faster commercialisation, manufacturing and distribution of vaccines.
You can watch a recording of the hearing here.
During the discussion, MEPs asked about global technology transfers, sharing patents, and how industry intends to update the vaccines in order to keep up with emerging variants. They also grilled CEOs on how the European Medicines Agency could speed up market approval at European level. Some MEPs asked whether an EU export ban on vaccines would help Europe compared to other countries that have introduced export bans. In their remarks, industry representatives highlighted the challenge of building production capacity for entirely new and complex products, and the international nature of supply chains.
“This was a world first: CEOs of the main vaccine manufacturers appearing before elected representatives. It’s good for transparency, and it’s good for democracy. It is crucial to regularly check accountability and commitments made. Moreover, the race to produce vaccines is intensifying and we are gearing up to use all available tools to support it. This was the point of this hearing”, said Environment, Public Health and Food Safety Chairman Pascal Canfin (Renew Europe, FR). “The European Parliament will play its role fully to win the vaccine deployment battle. The contact group put in place by the Parliament and Commission will further strengthen our role”, he added.
“Today’s challenge is about how to produce extremely complex products on a scale that is absolutely unprecedented. This is an industrial challenge”, said Industry, Research and Energy Committee Chairman Cristian Bușoi (EPP, RO). “This hearing was an exercise in democratic accountability. We wanted to know where the production bottlenecks are and to have a clear picture about the industry’s commitments and obligations. But we also want to help the industry deliver the doses, because our priority is to get vaccination done”.
Developing and distributing effective and safe vaccines against COVID-19 is the most effective response to the pandemic and is at the heart of the EU's recovery strategy. Given the importance of increasing production and access to vaccines, this hearing aimed to establish the facts and to find solutions to improve the roll-out of COVID-19 vaccines in Europe.
Another objective was to have an open discussion with the CEOs of the pharmaceutical industry, the Commission and other stakeholders on how to overcome impediments to speedier commercialisation, manufacturing, distribution and equitable access to the COVID-19 vaccines.
[ Ссылка ] #eudebates
